Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

Figure 9

The meta-analysis results for disease control rates (DCRs) and objective response rates (ORRs) in subgroups after afatinib treatment in advanced NSCLC with EGFR mutation: (a) comparison of DCRs in different status of brain metastases; (b) comparison of ORRs in different status of brain metastases; (c) comparison of DCRs in different mutation sites; and (d) comparison of ORRs in different mutation sites.

(a)

(b)

(c)

(d)